Table 1 Baseline histology stratified to cytological diagnosis and hrHPV status

From: Long-term protective effect of high-risk human papillomavirus testing in population-based cervical screening

  

Scc

Aden. Ca

CIN3

CIN2

Lesser abnormality

Normal

Total

Baseline cytology

Baseline hrHPV

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

Normal

+

77 (100)

77 (100)

 

2610 (100)

2610 (100)

BMD

+

3 (18.8)

3 (18.8)

2 (12.5)

8 (50.0)

16 (100)

 

1 (1.1)

6 (6.3)

88 (92.6)

95 (100)

>BMD

+

3 (27.3)

3 (27.3)

2 (18.2)

3 (27.3)

11 (100)

 

1 (100)

1 (100)

Total

 

3 (0.1)

6 (0.2)

6 (0.2)

11 (0.4)

2784 (99.1)

2810 (100)

  1. Scc, squamous cell carcinoma; Aden. Ca, adenocarcinoma; CIN1–3, cervical intra-epithelial neoplasia grade 1–3; lesser abnormality, CIN1 or abnormal smear; normal, histological or cytological normal diagnoses; BMD, borderline or mild dyskaryosis (Pap 2–3a mild dyskaryosis); >BMD, moderate dyskaryosis or worse (Pap 3a moderate dyskaryosis or worse); FU, follow-up. Baseline histology is presented for women with BMD and >BMD, with the annotation that for women with BMD histology was obtained after a serial abnormal smear after 6 or 18 months. For women with normal cytology (Pap 1), the follow-up data are presented in Table 2.